Abstract:Objective:To investigate the distribution of T-lymphocyte subsets and natural killer (NK)cells activity in peripheral blood from patients with pituitary adenomas and its clinical significance.Methods:A total of 215 patients with pituitary adenomas who were admitted to Department of Neurosurgery, the First Affiliated Hospital of Soochow University from March 2010 to October 2016 were prospectively enrolled in this study. In the same period, 95 healthy subjects were included as the healthy control group (referred to as the control group). Flow cytometry was used to detect the proportions of CD3 + , CD3 + CD4 + , CD3 + CD8 + , CD3 + CD25 + , CD3 + CD69 + , CD3 + HLA -DR + , CD3 -HLA -DR + and CD3 -CD(16+ 56) + (NK)cells in the peripheral blood of patients with different types of pituitary adenomas and the control group, which were compared between groups. The relationship between different proportions of lymphocyte subsets and clinical characteristics of patients with pituitary adenomas was explored. Results:In the pituitary adenoma group (215 cases), the proportion of CD3 + cells in peripheral blood was lower than that in the control group, while CD3 + CD25 + and CD3 + HLA -DR + cells were higher than the control group, and the differences were statistically significant (all P<0.05). Compared with the control group, (1) the proportion of CD3 + cells in peripheral blood of patients with non-functioning adenoma decreased, while the proportion of CD3 + CD25 + and CD3 + HLA -DR + cells increased (all P<0.05); (2) in the growth hormone(GH) adenoma and prolactin(PRL) adenoma patients, the proportions of CD3 + CD8 + , CD3 + CD25 + and CD3 + HLA -DR + cells increased, while the proportion of NK cells decreased (all P<0.05); (3) in patients with adrenocorticotropic hormone (ACTH) adenomas, the proportions of CD3 + CD4 + cells and NK cells decreased, while the proportions of CD3 + CD8 + , CD3 + CD25 + , CD3 + CD69 + and CD3 + HLA -DR + cells increased (all P<0.05). The proportion of CD3 + cells in the peripheral blood of patients with GH cell adenoma, gonadotropin cell adenoma, and naked cell adenoma (based on the 2017 WHO Classification of Pituitary Adenoma) was lower than that of the control group (all P<0.05). The proportion of NK cells in patients with GH cell adenoma, ACTH cell adenoma, multihormonal and dual hormone cell adenoma was lower than that of the control group (all P<0.05). The proportions of CD3 + CD25 + and CD3 + HLA -DR + cells in patients with GH cell adenoma, ACTH cell adenoma, PRL cell adenoma, gonadotropin cell adenoma, naked cell adenoma, multihormonal and dual hormone cell adenomas were higher than those in the control group (all P<0.05). In the PRL cell adenoma, multihormonal and dual hormone cell adenoma groups, the proportion of CD3 -HLA -DR + cells was lower than that of the control group ( P<0.05). The proportion of CD3 + cells in the giant pituitary adenoma group (tumor diameter >4 cm) was lower than that in the large adenoma group (1-4 cm) and microadenoma group (<1 cm) (both P<0.05). Compared with the non-invasive group, the proportion of CD3 + cells in the invasion group decreased, while the proportion of CD3 + CD25 + cells increased (both P<0.05). The proportion of NK cells in patients with recurrent pituitary adenoma was lower than that in patients with primary pituitary adenoma ( P<0.05). Conclusions:Patients with different types of pituitary adenomas have changes in immune function, which are mainly manifested as the function suppression of cellular immunity or NK cell. The suppression of immune function in patients with pituitary adenomas may be related to tumor burden, tumor invasiveness and recurrence.

The distribution of peripheral blood lymphocyte subsets and its clinical significance in patients with pituitary adenomas

Alterations in CD8+ Tregs, CD56+ Natural Killer Cells and IL-10 Are Associated with Invasiveness of Nonfunctioning Pituitary Adenomas (Nfpas)

Preliminary study of "overall levels of pituitary hormone" in non-functional pituitary adenoma patients

Relation of Proliferation and Apoptosis Indexes to the Invasiveness of Pituitary Adenomas

Targeting the Tumor Immune Microenvironment Could Become a Potential Therapeutic Modality for Aggressive Pituitary Adenoma

Detection of Programmed Death Ligand 1 Protein and CD8(+) Lymphocyte Infiltration in Plurihormonal Pituitary Adenomas A Case Report and Review of the Literatures

The Protein Expressions of PCNA, P53, Nm23-H 1 and Biological Behavior in Pituitary Adenoma

Immunopathological Study of Plurihormonal Pituitary Adenomas

Expression for Peroxisome Proliferator-Activated Receptor Gamma in Pituitary Adenomas - 38 Cases for Semi-Quantitative Immunohistochemical Analysis

Pathogenesis analysis of pituitary adenoma based on gene expression profiling.

Expressions and Significance of Letin,PTTG and Ki 67 in Invasive Pituitary Adenomas

Clinical and pathological features of 166 patients with nonfunctioning pituitary adenomas

[Preliminary Study of P16 Gene Expression in Pituitary Adenomas].

Pituitary adenoma: A clinicopathologic analysis of 180 cases

The Clinical and Pathological Characteristics of Invasive Pituitary Adenomas

Analysis of the Prognostic and Immunological Role of HSPB1 in Pituitary Adenoma: A Potential Target for Therapy

Expression of Pituitary Tumor Transforming Gene, Basic Fibroblast Growth Factor and Proliferating Cell Nuclear Antigen in Human Pituitary Adenomas: Correlation with Invasiveness

IMMU-49. DYNAMIC CHANGES AND PROGNOSTIC VALUE OF PERIPHERAL BLOOD LYMPHOCYTE SUBSETS IN INTRACRANIAL GERM CELL TUMORS

Detection of T lymphocyte subsets in patient with glioma

A Novel “total Pituitary Hormone Index” As an Indicator of Postoperative Pituitary Function in Patients Undergoing Resection of Pituitary Adenomas

Prognostic impact of peripheral natural killer cells in primary central nervous system lymphoma